NASDAQ:AKTS Aktis Oncology (AKTS) Stock Price, News & Analysis $16.31 +0.15 (+0.93%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$16.32 +0.01 (+0.03%) As of 11/17/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aktis Oncology Stock (NASDAQ:AKTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aktis Oncology alerts:Sign Up Key Stats Today's Range$15.60▼$16.4750-Day Range$14.59▼$24.0652-Week Range$13.96▼$34.19Volume473,264 shsAverage Volume352,308 shsMarket Capitalization$879.44 millionP/E RatioN/ADividend YieldN/APrice Target$35.63Consensus RatingModerate Buy Company Overview Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use. Aktis Oncology is based in Cambridge, Massachusetts, and focuses on research and clinical development of its radiopharmaceutical platform and product candidates.AI Generated. May Contain Errors. Read More Aktis Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreAKTS MarketRank™: 1.56229180546 of 5 starsAktis Oncology scored higher than 31% of companies evaluated by MarketBeat, and ranked 743rd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAktis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAktis Oncology has a consensus price target of $35.63, representing about 118.4% upside from its current price of $16.31.Amount of Analyst CoverageAktis Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Aktis Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aktis Oncology are expected to decrease in the coming year, from ($1.94) to ($2.51) per share.Price to Book Value per Share RatioAktis Oncology has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.23% of the float of Aktis Oncology has been sold short.Short Interest Ratio / Days to CoverAktis Oncology has a short interest ratio ("days to cover") of 16.02, which indicates bearish sentiment.Change versus previous monthShort interest in Aktis Oncology has recently increased by 2.60%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAktis Oncology does not currently pay a dividend.Dividend GrowthAktis Oncology does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.23 News SentimentAktis Oncology has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Aktis Oncology this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Aktis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aktis Oncology insiders have not sold or bought any company stock.Percentage Held by Institutions28.84% of the stock of Aktis Oncology is held by institutions.Read more about Aktis Oncology's insider trading history. Receive AKTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aktis Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKTS Stock News HeadlinesAktis: Q3 earnings snapshotNovember 12, 2026 | msn.comAktis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it. | Profits Run (Ad)Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial ProgressNovember 12, 2026 | finance.yahoo.comEarnings Flash (AKTS) Aktis Oncology, Inc. Reports Q3 Revenue $3.9M, vs. FactSet Est of $4.0MNovember 12, 2026 | marketscreener.comMAktis Oncology reports Q3 resultsNovember 12, 2026 | seekingalpha.comAktis Oncology (AKTS) Expected to Release Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comAktis Oncology: Padcev Is Building The Market It WantsOctober 14, 2026 | seekingalpha.comSee More Headlines AKTS Stock Analysis - Frequently Asked Questions How have AKTS shares performed this year? Aktis Oncology's stock was trading at $21.75 on January 1st, 2026. Since then, AKTS shares have decreased by 25.0% and is now trading at $16.31. How were Aktis Oncology's earnings last quarter? Aktis Oncology (NASDAQ:AKTS) announced its quarterly earnings data on Thursday, November, 12th. The technology company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.07. The technology company earned $3.91 million during the quarter, compared to the consensus estimate of $4.87 million. Aktis Oncology had a negative net margin of 706.81% and a negative trailing twelve-month return on equity of 26.86%. When did Aktis Oncology IPO? Aktis Oncology (AKTS) raised $300 million in an initial public offering on Friday, January 9th 2026. The company issued 17,650,000 shares at a price of $16.00-$18.00 per share. Who are Aktis Oncology's major shareholders? Aktis Oncology's top institutional shareholders include Blue Owl Capital Holdings LP (6.22%), State Street Corp (1.95%), Mirador Capital Partners LP (0.25%) and Jump Financial LLC (0.21%). Insiders that own company stock include Bioventures 2018 LP Mpm, Vida Ventures Ii, Llc, Helen Susan Kim, Ecor1 Capital, Llc and Ken Herrmann. View institutional ownership trends. How do I buy shares of Aktis Oncology? Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aktis Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aktis Oncology investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Inseego (INSG), Nokia (NOK), Micron Technology (MU) and Block (XYZ). Company Calendar Last Earnings11/12/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AKTS CIK2035832 Webwww.aktisoncology.com Phone(978) 237-4380FaxN/AEmployees79Year Founded2020Price Target and Rating Average Price Target for Aktis Oncology$35.63 High Price Target$40.00 Low Price Target$31.00 Potential Upside/Downside+118.4%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.73 million Net Margins-706.81% Pretax Margin-706.81% Return on Equity-26.86% Return on Assets-18.13% Debt Debt-to-Equity RatioN/A Current Ratio14.22 Quick Ratio14.22 Sales & Book Value Annual Sales$6.50 million Price / Sales135.30 Cash FlowN/A Price / Cash FlowN/A Book Value$8.51 per share Price / Book1.92Miscellaneous Outstanding Shares53,920,000Free FloatN/AMarket Cap$879.44 million OptionableOptionable BetaN/A Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:AKTS) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aktis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Share Aktis Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.